John Gill Biography and Net Worth

Director of Altimmune

Mr. Gill served as a director, president and chief executive officer of PharmAthene, Inc. from March 2015 until May 2017 and has served as a member of Altimmune’s board of directors since 2017. Mr. Gill was a founder of TetraLogic Pharmaceuticals and served as a director, president and chief executive officer from 2003 to 2013. Prior to founding TetraLogic Mr. Gill was executive vice president, chief operating officer and a director of 3-Dimensional Pharmaceuticals, a drug discovery and development company that was acquired by Johnson and Johnson during March 2003. Mr. Gill has previously held positions at SmithKline Beecham Corporation, now GlaxoSmithKline, where he served as a member of the research and development executive committee, chairman of the Research and Development Operating Committee, vice president research and development operations and finance, a founding member and partner of SR One Ltd., chief operating officer of SK&F Nova Pharmaceuticals and earlier in a variety of finance roles. Mr. Gill is a Certified Public Accountant and served in the United States Marine Corps.

What is John Gill's net worth?: The estimated net worth of John Gill is at least $42.63 thousand as of December 23rd, 2025. Mr. Gill owns 12,500 shares of Altimmune stock worth more than $42,625 as of April 21st. This net worth approximation does not reflect any other assets that Mr. Gill may own. Learn More about John Gill's net worth.
How do I contact John Gill?: The corporate mailing address for Mr. Gill and other Altimmune executives is 910 CLOPPER ROAD SUITE 201S, GAITHERSBURG MD, 20878. Altimmune can also be reached via phone at (240) 654-1450 and via email at [email protected]. Learn More on John Gill's contact information.
Has John Gill been buying or selling shares of Altimmune?: John Gill has not been actively trading shares of Altimmune during the last quarter. Most recently, on Tuesday, December 23rd, John Gill bought 12,500 shares of Altimmune stock. The stock was acquired at an average cost of $4.10 per share, with a total value of $51,250.00. Following the completion of the transaction, the director now directly owns 12,500 shares of the company's stock, valued at $51,250. Learn More on John Gill's trading history.
Who are Altimmune's active insiders?: Altimmune's insider roster includes Jerome Durso (CEO), John Gill (Director), Matthew Harris (Insider), Wayne Pisano (Director), and Gregory Weaver (CFO). Learn More on Altimmune's active insiders.
Are insiders buying or selling shares of Altimmune?: During the last twelve months, Altimmune insiders bought shares 6 times. They purchased a total of 55,527 shares worth more than $213,777.60. The most recent insider tranaction occured on March, 6th when CFO Gregory L Weaver bought 5,000 shares worth more than $17,700.00. Insiders at Altimmune own 1.6% of the company. Learn More about insider trades at Altimmune.
Information on this page was last updated on 3/6/2026.

John Gill Insider Trading History at Altimmune

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/23/2025	Buy	12,500	$4.10	$51,250.00	12,500
6/2/2017	Buy	1,000	$4.34	$4,340.00	83,224

John Gill Buying and Selling Activity at Altimmune

Altimmune Company Overview

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Today's Range

Now: $3.41

$3.39

$3.64

50 Day Range

MA: $3.76

$2.88

$4.65

2 Week Range

Now: $3.41

$2.87

$7.73

Volume

3,248,824 shs

Average Volume

4,136,972 shs

Market Capitalization

$443.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.34